AHRQ has posted a new evidence report, Treatment for Overactive Bladder in Women. For these reports, a team of folks reviews and evaluates the quality of the existing evidence on a topic, and looks at how that evidence addresses some key questions – in this case on prevalence and incidence of overactive bladder, treatment outcomes, comparisons of treatments, modifiers of outcomes, and costs.
I am particularly enthused about this one not only because it’s related to women’s health, but because it was done by the Evidence-based Practice Center (EPC) at my larger workplace, and I was actually involved in this topic through input on the search strategy and reviewing abstracts and full-text papers for inclusion/exclusion in the analysis. My colleague Rebecca Jerome was more deeply involved in the process, including some of the write-up, and is listed as one of the investigators.
Here’s the link to the PDF, if you’re interested. OBOS has some related content on urinary urgency and frequency and interstitial cystitis here, which touches on the confusion about treatment/mistreatment of urinary problems in women. Similarly, the AHRQ report notes that while overactive bladder is somewhat common and effectively resolving it may be important for women’s quality of life, the effects of the available treatments (including drug treatment) are considered “modest,” with little high quality literature available on the topic to guide treatment choices. As the Executive Summary concludes: “Women and their care providers deserve better information to guide their choices.”
[Cross-posted from Women’s Health News]